Pole des neurosciences, B4 neurology unit, CHU Purpan, Toulouse, France.
Pole des neurosciences, B4 neurology unit, CHU Purpan, Toulouse, France; Centre de ressources et de compétences Sclérose en plaques, CRC-SEP, CHU Purpan, Toulouse, France.
Mult Scler Relat Disord. 2020 Jun;41:102019. doi: 10.1016/j.msard.2020.102019. Epub 2020 Feb 22.
Few cases of late onset neutropenia after RITUXIMAB treatment (LONART) have been reported in patients with neuroinflammatory disorders. We conducted a retrospective analysis of patients treated with RITUXIMAB for neuromyelitis optica spectrum disorders (NMOSD), MOG-antibody-associated disease (MOGAD) and multiple sclerosis (MS) at the Toulouse University Hospital from November 2007 to October 2019. Ten patients with LONART were identified in a total of 385 patients: 4/25 were MOGAD patients, 2/20 were NMOSD patients and only 4/340 were MS patients (p < 0,05). Six required intravenous antibiotics whereas four were asymptomatic. Eight patients received new infusions of RITUXIMAB after resolution of their neutropenia. Neutropenia recurred in one patient.
已有少数神经炎性疾病患者在接受利妥昔单抗（RTX）治疗后出现迟发性中性粒细胞减少症（LONART）的报道。我们对 2007 年 11 月至 2019 年 10 月在图卢兹大学医院接受利妥昔单抗治疗的视神经脊髓炎谱系疾病（NMOSD）、MOG 抗体相关疾病（MOGAD）和多发性硬化症（MS）患者进行了回顾性分析。在总共 385 例患者中，发现了 10 例 LONART 患者：4/25 例为 MOGAD 患者，2/20 例为 NMOSD 患者，仅有 4/340 例为 MS 患者（p<0.05）。其中 6 例需要静脉使用抗生素，而 4 例无症状。中性粒细胞减少症缓解后，8 例患者再次接受了利妥昔单抗输注。其中 1 例患者中性粒细胞减少症再次复发。
